The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.
about
Crystal structure of the Golgi casein kinaseThe dynamic nature of the kinomeExpanding the number of 'druggable' targets: non-enzymes and protein-protein interactionsMolecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitorsA Novel Mechanism by Which Small Molecule Inhibitors Induce the DFG Flip in Aurora AInhibitors that stabilize a closed RAF kinase domain conformation induce dimerizationInsights into Aurora-A Kinase Activation Using Unnatural Amino Acids Incorporated by Chemical ModificationA conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivityNon-ATP-Mimetic Organometallic Protein Kinase InhibitorA genetically encoded 19F NMR probe for tyrosine phosphorylationProfile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assaysA comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determinationMolecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and CoevolutionATP-Competitive MLKL Binders Have No Functional Impact on NecroptosisThe Die Is Cast: Precision Electrophilic Modifications Contribute to Cellular Decision MakingStructure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions.BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity.Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation.Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor.Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.Discoidin domain receptors in disease.Targeting DNA repair pathways for cancer treatment: what's new?Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action.Histone acetyltransferases: Rising ancient counterparts to protein kinases.Chemistry-based functional proteomics for drug target deconvolution.Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agentsA broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.Energetic dissection of Gleevec's selectivity toward human tyrosine kinases.Generation and characterization of ATP analog-specific protein kinase Cδ.Extracellular metabolic energetics can promote cancer progressionBruton's TK inhibitors: structural insights and evolution of clinical candidates.Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanismIdentifying a kinase network regulating FGF14:Nav1.6 complex assembly using split-luciferase complementation.Anchor-based classification and type-C inhibitors for tyrosine kinases.Identification and Characterization of an Irreversible Inhibitor of CDK2.Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.Label-free electrochemical impedance detection of kinase and phosphatase activities using carbon nanofiber nanoelectrode arrays.Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms.The importance of tau phosphorylation for neurodegenerative diseases
P2860
Q24294846-C9F47F91-DF19-4CD3-8800-34127D0F258DQ26852588-BB1AE169-7B5B-43EF-81B8-7E81DC3A9CCBQ27003966-10DA6C46-CA28-4815-BC2E-99FEE8CB4035Q27673353-F470D172-F8EC-4412-B5D6-EC5467DE7531Q27676768-4EC29A09-DCD1-4F6D-916D-4592C6B73E9CQ27678182-907F7CA6-B9BD-4167-86F7-560FC54835BAQ27679437-2C0BC00C-D39C-488E-8905-B1028C37C9ECQ27680722-CD1F8C05-3FFB-4F13-9DEF-42D74998F88EQ27681838-DDEFAFA6-FB9F-4A9A-9979-CFD719F8F43AQ27684095-D56BEE00-ED54-430C-B7E9-2B9A00D9D074Q28487785-6C0A6CDB-5A2E-488E-9E19-F8CDEC307308Q28539535-28467ABC-D449-43F9-9549-27A3E4DAD9CFQ28548366-2F6C0D03-BF81-4FBC-8F36-E3D797944E93Q28553464-BF24FA50-63B3-445A-953C-22B4382FED40Q28821689-BFAD4C5D-A109-4D51-A9A5-EC380856550EQ30368961-E601F0AB-8541-4A32-B53C-79801F7E31BCQ30370399-00E7AFDF-D7C9-4EE1-B91E-68E83EED567FQ30391310-03C5EAA2-526C-4240-BB84-D3DBD55B4942Q30393936-FC351A03-1F84-4766-B4B5-CBC5868091A8Q30395364-954D820D-378A-46DB-9B69-69048B2E9DB5Q33605357-CB41876E-8E76-45F8-9FE1-1EC1332805AFQ34015040-DD5C848D-C898-4BED-AEDC-DBE49A149B30Q34265511-067B9BFB-C124-4783-A047-9F9EB0918162Q34313286-CA4C8323-A445-4509-9BF5-F7D8C7DD3537Q34342905-13B23C2C-938A-4B54-8F2A-491E292F1C89Q34554617-0B52E2AE-5205-4B19-B185-4C9B67D97352Q34582206-10121F1D-C98A-4D94-806A-832A80B40585Q34703677-23EE3B47-A136-47FE-9ED4-69FD37627AF4Q35002775-E3E49305-E788-42DB-891A-510EF506C0BCQ35033532-CA93B94A-4097-4A98-83F6-29B2F95F285BQ35181271-1847495C-948A-4BB8-A8B8-BAF05C43E304Q35509663-08290A0D-FB19-4F85-92E3-297F0BC6B99AQ35557270-C079D25D-0479-4462-B6A0-8D82ABD1DE03Q35745479-119CA407-6754-4740-A6F9-F31EC3A07AE4Q35759866-BEE9D0CC-4E5D-4697-A106-BDE0F8D513ACQ35894374-76207796-B864-4FED-AE02-80EBC712DEB4Q36203630-226F14B1-FFB9-4692-9116-DDAFD201E6EFQ36327175-4FE33644-A656-4B64-B065-E19A5400A652Q36491218-7007B5C6-A751-4EB2-9ED0-9AE63CE27C8EQ36968220-7A0185E1-47D2-4E17-A3FD-5966F7C44A24
P2860
The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The evolution of protein kinas ...... gonists of cellular signaling.
@en
The evolution of protein kinas ...... gonists of cellular signaling.
@nl
type
label
The evolution of protein kinas ...... gonists of cellular signaling.
@en
The evolution of protein kinas ...... gonists of cellular signaling.
@nl
prefLabel
The evolution of protein kinas ...... gonists of cellular signaling.
@en
The evolution of protein kinas ...... gonists of cellular signaling.
@nl
P1476
The evolution of protein kinas ...... gonists of cellular signaling.
@en
P2093
Arvin C Dar
Kevan M Shokat
P304
P356
10.1146/ANNUREV-BIOCHEM-090308-173656
P577
2011-01-01T00:00:00Z